http://www.malariajournal.com/content/6/1/28/comments The latest comments on the article 'Island-wide diversity in single nucleotide polymorphisms of the Plasmodium vivaxdihydrofolate reductase and dihydropteroate synthetase genes in Sri Lanka' 2007-04-14T10:20:54Z http://www.malariajournal.com/content/6/1/28/comments#276537 <p>We have been made aware of some serious flaws in the text regarding the drug treatment guidelines in Sri Lanka that we feel we have to correct. We claim that SP is used as second line drug against both <i>P. falciparum</i> and <i>P. vivax</i> infections, this is not correct: SP is only used against <i>P. falciparum</i> treatment failures. </p><p>In abstract, should be read as:</p><p>&#8220;In Sri Lanka, chloroquine (CQ) with primaquine (PQ) and SP with PQ is used as first and second line treatment, respectively, against uncomplicated <i>Plasmodium falciparum</i> and resistant <i>P. falciparum infections</i>. CQ/PQ is still efficacious against <i>P. falciparum</i> infections, thus SP is rarely used and it is assumed that the prevalence of SNPs related to <i>P. vivax</i> SP resistance is low.&#8221;</p><p>In the discussion, should be read as:</p><p>&#8220;The present descriptive study analysed sulphadoxine/pyrimethamine (SP) resistance-related SNPs in the <i>P. vivax dhfr</i> and <i>Pvdhps</i> genes in samples originating from nine districts in Sri Lanka, a country were both CQ and SP (in combination with primaquine) is still regarded as efficient treatment against uncomplicated <i>P. falciparum</i> and resistant forms of <i>P. falciparum</i> infections, respectively.&#8220;</p><p>This does however not influence the conclusions of this study, on the contrary: when SP is not used at all against <i>P. vivax</i> infections then it is intriguing that we find quite a high frequency of SP-resistance related mutations. </p> Michael Alifrangis 2007-04-14T10:20:54Z http://www.malariajournal.com/content/6/1/28 Schousboe et al. Malaria Journal 6 28 Fri Mar 09 15:24:01 GMT 2007